PHARMAGNOSE VIOTECHNOLOGIKI ANONYMI ETAIREIA

Their core work

Pharmagnose Biotechnologies is a Greek biotech SME based in Chalkida that specializes in the extraction, chemical profiling, and biomedical application of natural bioactive compounds — with a particular focus on olive-derived molecules such as oleocanthal and oleacein. They work at the intersection of natural product chemistry and pharmaceutical science, translating Mediterranean agricultural by-products (especially olive mill waste) into commercially viable nutraceuticals, cosmetics, and therapeutic candidates. Their more recent work targets the molecular mechanisms behind arthritic diseases, applying expertise in inflammation biology to develop personalized treatment approaches. As an industry SME partner in European research consortia, they bridge academic discovery science and practical product development.

What they specialise in

How they've shifted over time

Their H2020 trajectory begins with broad natural product science: extracting, analyzing, and profiling olive bioactives across multiple application sectors — food, cosmetics, supplements, and early-stage pharma. By 2019 the focus narrows sharply to a single disease target — arthritis — and to the molecular mechanisms of inflammation resolution rather than compound discovery. The through-line is inflammation biology, but the shift is unmistakable: from characterizing what olive polyphenols can do in general, to understanding how to cure a specific inflammatory disease with personalized therapies.

Pharmagnose is moving from broad natural product characterization toward targeted therapeutic development for inflammatory diseases, signaling a growing pharmaceutical orientation that may lead to drug development or clinical translation partnerships.

How they like to work

Pharmagnose has participated in both of their H2020 projects as a partner, never as coordinator — a pattern consistent with an SME offering specialized industrial expertise within academically led consortia. Both projects used MSCA schemes (RISE and ITN), which are designed for researcher mobility and training networks, meaning Pharmagnose serves as an industry host and application partner rather than a research driver. With 30 unique partners across 15 countries from just two projects, they clearly operate in large, international networks — suggesting they are comfortable navigating multi-partner consortia and contributing a defined, bounded role.

Despite only two funded projects, Pharmagnose has connected with 30 distinct consortium partners across 15 countries — an average of 15 partners per project, consistent with the large international consortia typical of MSCA-ITN and MSCA-RISE schemes. Their network likely spans both EU member states and associated or third countries given RISE's international mobility dimension.

What sets them apart

Pharmagnose occupies a rare niche as a Greek biotech SME with documented EU-funded expertise in both olive polyphenol science and inflammatory disease therapeutics — two areas that are individually common in Greece but rarely combined at the company level. Their position as an industry partner in MSCA networks means they have direct experience hosting and co-supervising researchers, which makes them an attractive partner for academic groups seeking commercial grounding. For a consortium building around Mediterranean bioeconomy, natural anti-inflammatory compounds, or arthritis research, they bring credibility as a practitioner rather than purely a research institution.

Highlights from their portfolio

• ArthritisHeal
  Their largest project by funding (EUR 243,018) and their most therapeutically ambitious, targeting the molecular basis of arthritic disease and personalized treatment — a significant step beyond ingredient characterization toward pharmaceutical development.
• Olive-Net
  A cross-sector MSCA-RISE project that established their core expertise in olive bioactive extraction and profiling, spanning food, cosmetic, and pharmaceutical applications across an international partner network.